ASO targeting PKM splicing increases the PKM1 to PKM2 ratio, thereby redirecting glucose carbons from anabolic processes to the tricarboxylic acid (TCA) cycle in hepatocellular carcinoma and suppressing the liver-tumor formation and growth [110]. The gene discussed is PKM; the disease is medical procedure.